HAVAH Therapeutics

HavaH’s mission is to develop therapies with reduced side effects and early prevention of breast cancers including hormonal refractory ER+ breast cancer and metastatic cancer. Havah uses targeted modulation of the hormonal balance in the breast to achieve a more nuanced hormonal regulation than traditional hormonal therapies. HavaH is developing innovative, proprietary hormonal therapies that aim to improve quality of life for women across the world. HavaH brings together a world-class team passionate about helping women live lives free from the suffering caused by breast pain, debilitating menopausal symptoms and breast cancer. Havah has extensive clinical experience with T+Ai™ having generated data from more than 1,000 Australian women with breast disease through an ongoing open label cohort study, with critical safety pharmacokinetic and early efficacy data already demonstrated.